{
  "personality": null,
  "timestamp": "2025-10-13T04:36:26.541400",
  "category": "Health",
  "news_summary": "Recent research highlights breakthroughs in reducing diabetes and colorectal cancer risks through diet and medication, potential treatments for fatty liver disease, and new genetic insights into aging from naked mole rats.",
  "news_summary_fr": "La recherche récente met en évidence des avancées dans la réduction des risques de diabète et de cancer colorectal par le régime alimentaire et les médicaments, des traitements potentiels de la maladie du foie gras et de nouvelles connaissances génétiques sur le vieillissement chez les rats taupes nus.",
  "news_summary_es": "Investigaciones recientes destacan avances en la reducción de los riesgos de diabetes y cáncer colorrectal mediante la dieta y la medicación, tratamientos potenciales para la enfermedad del hígado graso y nuevos conocimientos genéticos sobre el envejecimiento a partir de ratas topo desnudas.",
  "articles": [
    {
      "title": "Scientists found a smarter Mediterranean diet that cuts diabetes risk by 31%",
      "summary": "Spanish researchers found that combining a calorie-reduced Mediterranean diet with exercise and professional support cut type 2 diabetes risk by 31%. Participants also lost weight and reduced waist size, proving that small, consistent lifestyle shifts can yield major health gains. Experts say this realistic approach could be integrated globally to tackle diabetes and obesity epidemics.",
      "content": "Eating a Mediterranean-style diet with fewer calories, adding moderate physical activity, and receiving professional guidance for weight management can lower the risk of developing type 2 diabetes by 31%. That is the key finding of PREDIMED-Plus, a large clinical trial led in Spain by the University of Navarra together with more than 200 researchers from 22 universities, hospitals, and research institutes. The project was carried out in over 100 primary care centers within Spain's National Health System.\n\nLaunched in 2013 after the University of Navarra received an Advanced Grant of over €2 million from the European Research Council (ERC), PREDIMED-Plus is the largest nutrition trial ever conducted in Europe. Between 2014 and 2016, additional institutions joined the effort, bringing total funding above 15 million euros. Most of the support came from the Carlos III Health Institute (ISCIII) and the Center for Biomedical Research Network (CIBER), through its divisions on Physiopathology of Obesity and Nutrition (CIBEROBN), Epidemiology and Public Health (CIBERESP), and Diabetes and Associated Metabolic Diseases (CIBERDEM).\n\nThe study, published in Annals of Internal Medicine, followed 4,746 adults between the ages of 55 and 75 who were overweight or obese and had metabolic syndrome but no prior history of cardiovascular disease or diabetes. Over six years, researchers compared two groups. One group adopted a calorie-reduced Mediterranean diet (about 600 fewer kilocalories per day), engaged in moderate exercise such as brisk walking and strength and balance training, and received professional counseling. The other group continued a traditional Mediterranean diet without calorie limits or exercise advice.\n\nThe results revealed that the participants who followed the calorie-reduced diet and exercise plan not only reduced their diabetes risk but also lost more weight and trimmed more from their waistlines. On average, they lost 3.3 kg and 3.6 cm from their waist, compared to 0.6 kg and 0.3 cm in the control group. This translated to preventing about three new cases of type 2 diabetes for every 100 participants -- a meaningful benefit for public health.\n\n\"Diabetes is the first solid clinical outcome for which we have shown -- using the strongest available evidence -- that the Mediterranean diet with calorie reduction, physical activity and weight loss is a highly effective preventive tool,\" said Miguel Ángel Martínez-González, Professor of Preventive Medicine and Public Health at the University of Navarra, Adjunct Professor of Nutrition at Harvard University, and one of the principal investigators of the project. \"Applied at scale in at-risk populations, these modest and sustained lifestyle changes could prevent thousands of new diagnoses every year. We hope soon to show similar evidence for other major public health challenges.\"\n\nType 2 Diabetes: A Preventable Global Epidemic\n\nAccording to the International Diabetes Federation, type 2 diabetes now affects over 530 million people around the world. Its rise is fueled by urbanization (unhealthy diets, sedentary lifestyles, reduced physical activity), an aging population, and increasing rates of overweight and obesity. In Spain, an estimated 4.7 million adults live with diabetes -- mostly type 2 -- giving the country one of the highest rates in Europe, where total cases exceed 65 million. In the United States, roughly 38.5 million people have diabetes, and the disease carries some of the highest per-patient healthcare costs worldwide. Experts emphasize that prevention is crucial to slow this escalating crisis, which greatly increases the risk of heart, kidney, and metabolic complications.\n\n\"The Mediterranean diet acts synergistically to improve insulin sensitivity and reduce inflammation. With PREDIMED-Plus, we demonstrate that combining calorie control and physical activity enhances these benefits,\" explained Miguel Ruiz-Canela, Professor and Chair of Preventive Medicine and Public Health Department at the University of Navarra's School of Medicine and first author of the study. \"It is a tasty, sustainable and culturally accepted approach that offers a practical and effective way to prevent type 2 diabetes -- a global disease that is, to a large extent, avoidable.\"\n\nInternational Relevance and Support for a Realistic and Scalable Strategy\n\nAnnals of Internal Medicine accompanied the publication with an editorial by Sharon J. Herring and Gina L. Tripicchio, nutrition and public health experts at Temple University (Philadelphia, USA). They praised the intervention's clinical relevance and its potential as a preventive model for type 2 diabetes. Furthermore, they warn that replicating similar strategies outside the Mediterranean context -- such as in the U.S. -- requires overcoming structural barriers, including unequal access to healthy foods, the limitations of the urban environment, and the lack of professional guidance. In this scenario, they advocate strengthening public policies that promote more nutritious and more equitable environments. At a time when new drugs against obesity and diabetes are grabbing headlines, PREDIMED-Plus demonstrates that modest, sustained lifestyle changes can still deliver powerful health benefits.\n\nThe PREDIMED-Plus project (2013-2024), which involves different patients, is a continuation of the PREDIMED study (2003-2010). This study demonstrated that following a Mediterranean diet enriched with extra-virgin olive oil or nuts reduces the risk of cardiovascular disease by 30%. Researchers emphasize that primary care providers can integrate the new intervention as a sustainable, cost-efficient strategy to prevent type 2 diabetes on a large scale.\n\nParticipating Institutions\n\nThe PREDIMED-Plus trial has assembled a broad network of investigators from across Spain. In order of the number of participants, the study included researchers from the following institutions: the University of Navarra and the Navarra Health Service (2 centers), Hospital Clínic de Barcelona (2 centers), University of Valencia, Rovira i Virgili University (Reus), IMIM-Hospital del Mar, Miguel Hernández University (Alicante), Son Espases Hospital (Palma de Mallorca), University of Malaga, Reina Sofía Hospital (Córdoba) and University of Granada. In addition, Bioaraba and the UPV/EHU (Vitoria), the University of the Balearic Islands, the Hospital Virgen de la Victoria (Malaga), the University of Las Palmas de Gran Canaria, the University of Leon, the Primary Health Care District of Seville, the Fundación Jiménez Díaz (Madrid), the Hospital de Bellvitge, the Hospital Clínico San Carlos (Madrid), the University of Jaen, and the IMDEA Food Institute (Madrid) have also participated.\n\nThe project also benefited from international collaboration with the Harvard T.H. Chan School of Public Health (USA). Most of the participating researchers are affiliated with the CIBEROBN, CIBERESP, or CIBERDEM research networks.",
      "url": "https://www.sciencedaily.com/releases/2025/10/251012054621.htm",
      "source": "Latest Science News -- ScienceDaily",
      "published": "2025-10-13",
      "sentiment_score": 0.9,
      "reasoning": "The article reports a significant, large-scale clinical trial demonstrating that a calorie-reduced Mediterranean diet combined with exercise and professional support can reduce type 2 diabetes risk by 31%. This finding has broad public health implications given the global diabetes epidemic, offers a practical, scalable prevention strategy, and is supported by robust scientific evidence from a major European study.",
      "category": "Health",
      "personality_title": "New Mediterranean diet plan cuts type 2 diabetes risk by 31%",
      "personality_presentation": "**Context** – Type 2 diabetes is a disease that affects millions of people worldwide. It happens when the body cannot control blood sugar properly. Eating habits and exercise can help prevent it, but finding the best plan has been a challenge.\n\n**What happened** – A large study in Spain called PREDIMED-Plus tested a new approach. From 2013 to 2024, nearly 5,000 adults aged 55 to 75 who were overweight tried two ways of following the Mediterranean diet. One group ate fewer calories, exercised moderately, and got help from health professionals. The other group followed the traditional Mediterranean diet without special calorie limits or exercise advice. After six years, the first group lowered their chance of getting type 2 diabetes by 31%.\n\n**Impact** – This result shows that small, steady changes in eating and moving can have a big effect on health. The group that followed the new plan lost more weight—about 3.3 kilograms on average—and reduced their waist size more than the other group. This means fewer people developed diabetes, which can lead to serious health problems. The study offers a clear, science-backed way to help prevent diabetes in many people.\n\n**What's next step** – Researchers hope doctors will start using this combined diet and exercise plan to help people at risk. They also want to test if similar programs can work outside Spain, even in places with different foods and lifestyles. Public health experts suggest creating policies to make healthy foods and exercise easier for everyone, so this method can reach more people.\n\n**One-sentence takeaway** – A calorie-reduced Mediterranean diet combined with exercise and professional support can significantly lower the risk of type 2 diabetes in older adults.\n",
      "personality_title_fr": "Un nouveau régime méditerranéen réduit de 31 % le risque de diabète de type 2",
      "personality_presentation_fr": "**Contexte** – Le diabète de type 2 touche des millions de personnes dans le monde. Il survient lorsque le corps ne contrôle pas correctement le taux de sucre dans le sang. L’alimentation et l’exercice peuvent aider à le prévenir, mais trouver la meilleure méthode était difficile.\n\n**Ce qui s’est passé** – Une grande étude en Espagne, appelée PREDIMED-Plus, a testé une nouvelle approche. De 2013 à 2024, près de 5 000 adultes âgés de 55 à 75 ans en surpoids ont suivi deux versions du régime méditerranéen. Un groupe a réduit ses calories, fait de l’exercice modéré et reçu un accompagnement professionnel. L’autre groupe a suivi le régime méditerranéen traditionnel sans limite de calories ni conseils d’exercice. Après six ans, le premier groupe a réduit son risque de diabète de type 2 de 31 %.\n\n**Impact** – Ce résultat montre que de petits changements réguliers dans l’alimentation et l’activité physique peuvent avoir un grand effet sur la santé. Le groupe qui a suivi le nouveau régime a perdu plus de poids – environ 3,3 kilogrammes en moyenne – et a réduit davantage la taille de sa taille. Cela signifie que moins de personnes ont développé le diabète, qui peut causer de graves problèmes de santé. Cette étude offre une méthode claire et scientifique pour aider à prévenir le diabète chez beaucoup de personnes.\n\n**Prochaine étape** – Les chercheurs espèrent que les médecins commenceront à utiliser ce régime combiné à l’exercice pour aider les personnes à risque. Ils veulent aussi vérifier si des programmes similaires peuvent fonctionner en dehors de l’Espagne, même dans des pays avec des aliments et modes de vie différents. Les experts en santé publique suggèrent de créer des politiques pour faciliter l’accès à des aliments sains et à l’exercice pour tous, afin que cette méthode bénéficie au plus grand nombre.\n\n**En une phrase** – Un régime méditerranéen hypocalorique associé à l’exercice et à un accompagnement professionnel peut réduire significativement le risque de diabète de type 2 chez les adultes plus âgés.\n",
      "personality_title_es": "Nuevo plan de dieta mediterránea reduce en un 31 % el riesgo de diabetes tipo 2",
      "personality_presentation_es": "**Contexto** – La diabetes tipo 2 afecta a millones de personas en todo el mundo. Ocurre cuando el cuerpo no controla bien el azúcar en la sangre. La alimentación y el ejercicio pueden ayudar a prevenirla, pero encontrar el mejor método ha sido un reto.\n\n**Qué pasó** – Un gran estudio en España llamado PREDIMED-Plus probó un nuevo enfoque. Entre 2013 y 2024, casi 5,000 adultos entre 55 y 75 años con sobrepeso siguieron dos versiones de la dieta mediterránea. Un grupo redujo las calorías, hizo ejercicio moderado y recibió apoyo profesional. El otro grupo siguió la dieta mediterránea tradicional sin límites de calorías ni consejos de ejercicio. Después de seis años, el primer grupo redujo su riesgo de diabetes tipo 2 en un 31 %.\n\n**Impacto** – Este resultado muestra que pequeños cambios constantes en la dieta y el movimiento pueden tener un gran efecto en la salud. El grupo que siguió el nuevo plan perdió más peso—alrededor de 3.3 kilogramos en promedio—y redujo más su cintura. Esto significa que menos personas desarrollaron diabetes, que puede causar problemas graves de salud. El estudio ofrece una forma clara y respaldada por la ciencia para ayudar a prevenir la diabetes en muchas personas.\n\n**Próximo paso** – Los investigadores esperan que los médicos empiecen a usar este plan combinado de dieta y ejercicio para ayudar a personas en riesgo. También quieren probar si programas similares pueden funcionar fuera de España, incluso en lugares con diferentes alimentos y estilos de vida. Los expertos en salud pública sugieren crear políticas para facilitar el acceso a alimentos saludables y ejercicio para todos, para que este método llegue a más personas.\n\n**Mensaje en una frase** – Una dieta mediterránea con reducción de calorías, combinada con ejercicio y apoyo profesional, puede reducir significativamente el riesgo de diabetes tipo 2 en adultos mayores.\n",
      "image_url": "public/images/news_image_Scientists-found-a-smarter-Mediterranean-diet-that.png",
      "image_prompt": "A warm, detailed painting of a vibrant Mediterranean table set with colorful bowls of fresh vegetables, olives, nuts, and a bottle of olive oil beside a gently flowing path where abstract human silhouettes walk briskly and stretch, symbolizing moderate exercise and healthy lifestyle, all rendered in soft natural earth tones and subtle greens, evoking a sense of balance, vitality, and well-being."
    },
    {
      "title": "Low-dose aspirin may cut risk of colorectal cancer returning in key patients, study shows",
      "summary": "BY THE OPTIMIST DAILY EDITORIAL TEAM A low-cost, widely available drug might offer major protection against one of the most common cancers worldwide. New research out of Sweden suggests that a low daily dose of aspirin could significantly reduce the chance of colorectal cancer returning after surgery, but only for certain patients with specific genetic […]\nThe post Low-dose aspirin may cut risk of colorectal cancer returning in key patients, study shows first appeared on The Optimist Daily: Making Solutions the News.",
      "content": "BY THE OPTIMIST DAILY EDITORIAL TEAM\n\nA low-cost, widely available drug might offer major protection against one of the most common cancers worldwide. New research out of Sweden suggests that a low daily dose of aspirin could significantly reduce the chance of colorectal cancer returning after surgery, but only for certain patients with specific genetic mutations.\n\nThe findings, published in the New England Journal of Medicine, stem from the Alascca trial led by Professor Anna Martling at the Karolinska Institute. Her team followed more than 3,500 colorectal cancer patients across Sweden, Norway, Denmark, and Finland to determine whether aspirin could play a role in preventing cancer recurrence.\n\nA striking reduction in recurrence risk\n\nAfter analyzing genetic tests from 2,980 participants, the researchers identified that 1,103 individuals, which amounts to about 37 percent, had mutations in a pathway called PI3K, known to be involved in colorectal cancer. These patients were randomly assigned to receive either 160 milligrams of aspirin daily or a placebo for three years following surgery.\n\nThe study resulted in a dramatic 55 percent reduction in the risk of cancer returning among those who took aspirin. “If you had these mutations, the risk of the cancer coming back was lowered by more than 50 percent. It is a huge effect,” said Martling. “I think this will change clinical practice.”\n\nUnderstanding why aspirin works\n\nWhile aspirin has long been studied for its protective benefits in cardiovascular health, its role in cancer prevention has gained growing attention in recent years. In this trial, the drug appeared to suppress inflammation, disrupt the PI3K pathway, and reduce the activity of blood platelets, which can shield tumor cells from the body’s immune system.\n\nEarlier research had shown aspirin’s ability to help prevent colorectal cancer in individuals with hereditary conditions like Lynch syndrome, but its effectiveness in preventing recurrence after tumor removal remained an open question until now.\n\nGenetic testing could guide treatment\n\nMartling emphasized the importance of routine genetic testing for colorectal cancer patients. By identifying those with PI3K mutations, healthcare providers could tailor post-surgical care and offer aspirin as a targeted, cost-effective prevention strategy.\n\n“It’s a widely available drug that is extremely inexpensive,” Martling noted. “We now have strong evidence to support offering it to the right group of patients.”\n\nWeighing benefits and risks\n\nDespite its accessibility and affordability, aspirin is not without risks. In the trial, four participants experienced severe side effects possibly related to aspirin, including gastrointestinal bleeding, an allergic reaction, and brain hemorrhage. One patient’s death may have been linked to the drug.\n\nThese findings underscore the need for careful risk-benefit assessments and consultation with healthcare providers before beginning long-term aspirin use, especially for individuals with underlying conditions or bleeding risks.\n\nA step forward in personalized cancer care\n\nExperts believe this research adds to a growing body of evidence supporting aspirin as a tool in cancer prevention, but only when used strategically.\n\nDr. Catherine Elliott, director of research at Cancer Research UK, welcomed the findings. “There is increasing evidence that in certain groups of people, low-dose aspirin can offer protection from bowel cancer,” she said. She also pointed to the CaPP3 trial, which found a similar benefit for individuals with Lynch syndrome.\n\n“We need larger, high-quality studies like CaPP3 and this recent research to confirm who would most benefit from taking aspirin to help them live longer, better lives, free from the fear of cancer,” Elliott declared.\n\nSource study: The New England Journal of Medicine—Low-dose aspirin for PI3K-altered Localized colorectal cancer",
      "url": "https://www.optimistdaily.com/2025/10/low-dose-aspirin-may-cut-risk-of-colorectal-cancer-returning-in-key-patients-study-shows/?utm_source=rss&utm_medium=rss&utm_campaign=low-dose-aspirin-may-cut-risk-of-colorectal-cancer-returning-in-key-patients-study-shows",
      "source": "The Optimist Daily: Making Solutions the News",
      "published": "2025-10-13",
      "sentiment_score": 0.9,
      "reasoning": "The article reports a significant medical breakthrough showing that low-dose aspirin can reduce colorectal cancer recurrence by 55% in patients with specific genetic mutations, offering a low-cost, widely accessible treatment with broad implications for cancer care and personalized medicine.",
      "category": "Health",
      "personality_title": "Low-dose aspirin cuts risk of colorectal cancer returning in patients with specific gene mutation",
      "personality_presentation": "**Context** – Colorectal cancer is one of the most common cancers worldwide. After surgery to remove tumors, many patients face the risk of the cancer coming back. Researchers have been looking for ways to lower this risk using affordable and widely available treatments.\n\n**What happened** – A team from Sweden, led by Professor Anna Martling at the Karolinska Institute, studied over 3,500 patients with colorectal cancer across four countries. They gave a low daily dose of aspirin (160 mg) or a placebo to patients after surgery for three years. They found that patients with a certain genetic mutation in the PI3K pathway who took aspirin had a 55% lower chance of the cancer returning.\n\n**Impact** – This is important because aspirin is cheap and easy to get, and this finding offers a new way to help patients with specific genetics reduce their risk of cancer coming back. The study shows that testing patients’ genes can help doctors decide who might benefit from aspirin, making cancer treatment more personalized.\n\n**What's next step** – Doctors will likely start using genetic tests more often to find patients with the PI3K mutation. More studies are needed to confirm these results and make sure aspirin’s benefits outweigh the risks, as some patients experienced serious side effects. Researchers will also explore how to safely use aspirin in cancer care.\n\n**One-sentence takeaway** – A low dose of aspirin can cut the chance of colorectal cancer returning by over half in patients with a specific gene mutation, offering a low-cost option for personalized treatment.",
      "personality_title_fr": "L’aspirine à faible dose réduit le risque de récidive du cancer colorectal chez certains patients",
      "personality_presentation_fr": "**Contexte** – Le cancer colorectal est l’un des cancers les plus courants dans le monde. Après une opération pour enlever une tumeur, de nombreux patients risquent que le cancer revienne. Les chercheurs cherchent des traitements abordables et accessibles pour réduire ce risque.\n\n**Ce qui s’est passé** – Une équipe suédoise dirigée par la professeure Anna Martling de l’Institut Karolinska a étudié plus de 3 500 patients atteints du cancer colorectal dans quatre pays. Ils ont donné une faible dose quotidienne d’aspirine (160 mg) ou un placebo pendant trois ans après l’opération. Ils ont découvert que les patients porteurs d’une mutation génétique dans la voie PI3K qui prenaient de l’aspirine avaient 55 % moins de risques que le cancer revienne.\n\n**Impact** – Cela est important car l’aspirine est peu coûteuse et facile à obtenir. Cette découverte offre une nouvelle solution pour aider certains patients à réduire le risque de récidive. Le test génétique peut aider les médecins à cibler les patients qui bénéficieront le plus, rendant le traitement plus personnalisé.\n\n**Prochaine étape** – Les médecins devraient utiliser davantage les tests génétiques pour détecter la mutation PI3K. D’autres études sont nécessaires pour confirmer ces résultats et assurer la sécurité de l’aspirine, car certains patients ont eu des effets secondaires graves. Les chercheurs vont aussi étudier comment utiliser l’aspirine en toute sécurité dans les soins du cancer.\n\n**Une phrase clé** – Une faible dose d’aspirine peut réduire de plus de moitié le risque de retour du cancer colorectal chez les patients avec une mutation génétique spécifique, offrant une option peu coûteuse pour un traitement personnalisé.",
      "personality_title_es": "La aspirina en dosis bajas reduce el riesgo de recaída del cáncer colorrectal en pacientes con mutación genética específica",
      "personality_presentation_es": "**Contexto** – El cáncer colorrectal es uno de los cánceres más comunes en el mundo. Después de una cirugía para eliminar tumores, muchos pacientes corren el riesgo de que el cáncer regrese. Los investigadores buscan tratamientos accesibles y económicos para reducir este riesgo.\n\n**Qué pasó** – Un equipo de Suecia, liderado por la profesora Anna Martling del Instituto Karolinska, estudió a más de 3,500 pacientes con cáncer colorrectal en cuatro países. Durante tres años después de la cirugía, algunos pacientes recibieron una dosis baja diaria de aspirina (160 mg) y otros un placebo. Descubrieron que los pacientes con una mutación genética en la vía PI3K que tomaron aspirina tuvieron un 55% menos de riesgo de que el cáncer regresara.\n\n**Impacto** – Esto es importante porque la aspirina es barata y fácil de conseguir. Este hallazgo ofrece una nueva forma de ayudar a los pacientes con genética específica a reducir el riesgo de recaída. Las pruebas genéticas pueden ayudar a los médicos a decidir quién se beneficiará más, haciendo el tratamiento más personalizado.\n\n**Próximo paso** – Los médicos probablemente usarán más pruebas genéticas para identificar a los pacientes con la mutación PI3K. Se necesitan más estudios para confirmar estos resultados y asegurar que los beneficios de la aspirina superen los riesgos, ya que algunos pacientes tuvieron efectos secundarios graves. Los investigadores también explorarán cómo usar la aspirina de manera segura en el tratamiento del cáncer.\n\n**Una frase clave** – Una dosis baja de aspirina puede reducir en más de la mitad el riesgo de recaída del cáncer colorrectal en pacientes con una mutación genética específica, ofreciendo una opción económica para un tratamiento personalizado.",
      "image_url": "public/images/news_image_Low-dose-aspirin-may-cut-risk-of-colorectal-cancer.png",
      "image_prompt": "A warm, detailed painting of a delicate aspirin tablet gently resting beside a stylized DNA double helix strand glowing softly with highlighted segments to represent the PI3K mutation, set against a calm, natural background evoking healing and hope, with subtle abstract shapes symbolizing the immune system’s protective response surrounding them."
    },
    {
      "title": "Two common drugs could reverse fatty liver disease",
      "summary": "Researchers at the University of Barcelona found that combining pemafibrate and telmisartan significantly reduces liver fat and cardiovascular risks in MASLD models. The drug duo works better together than alone, likely due to complementary mechanisms. They also uncovered a new role for the PCK1 protein in fat metabolism.",
      "content": "Metabolic dysfunction-associated steatotic liver disease is currently the most widespread liver disorder globally, affecting roughly one in three adults. It occurs when excess fat builds up inside liver cells, leading to serious liver damage and a higher risk of death from cardiovascular disease.\n\nResearchers at the University of Barcelona have now found a promising approach that could change how this condition is treated. Their study, published in Pharmacological Research, reports that two existing drugs, pemafibrate and telmisartan, significantly reduced fat buildup in animal models of metabolic liver disease. The findings also suggest that using these medications together could ease liver damage while lowering related heart and blood vessel complications. Because available treatments for this disease remain very limited, the results point to a potentially safer and more effective therapeutic option.\n\nThe research was led by Marta Alegret, a professor at the University of Barcelona's Faculty of Pharmacy and Food Sciences, and a member of the Institute of Biomedicine of the UB (IBUB) and the CIBER Area for Physiopathology of Obesity and Nutrition (CIBEROBN). The work was conducted in collaboration with scientists from the Santa Creu i Sant Pau Hospital Research Institute, the Hospital Clínic de Barcelona, the CIBER Area for Cardiovascular Diseases (CIBERCV), and Uppsala University (Sweden).\n\n​​​​​​​Drug repurposing, a promising and cost-effective strategy\n\nTo date, most new experimental compounds developed for metabolic dysfunction-associated steatotic liver disease (MASLD) -- formerly known as fatty liver disease -- have failed during clinical trials, often because of safety concerns. This has turned attention toward drug repurposing, a strategy that explores new uses for medications already proven to be safe in humans. Such an approach is not only faster and more affordable but also particularly valuable for treating the early, often symptom-free stages of MASLD.\n\n\"We have focused on these phases with the aim of preventing the disease from progressing to more severe stages. But for a drug to be used in these early stages, it must have a good safety profile in humans,\" explains Marta Alegret. \"That is why we have studied drugs already on the market for other pathologies, which have been shown to be very safe and could have a potential benefit in the treatment of MASLD,\" she adds.\n\nIn this study, the team evaluated the potential of two approved medications, given separately and together: a lipid-lowering agent (pemafibrate) and an antihypertensive drug (telmisartan). The first is marketed only in Japan, while the second is widely used for high blood pressure. Both are prescribed to reduce cardiovascular risk. \"Mortality from cardiovascular causes is significant in patients with MASLD, and often these patients also have these two risk factors together,\" Alegret stresses.\n\nZebrafish larvae, an alternative model for studying the disease\n\nTo confirm the efficacy of the drugs and explore their mechanism of action, the researchers have applied them to a rat model of the disease and, subsequently, to a zebrafish larval model. \"In recent years, zebrafish have emerged as an interesting alternative model that facilitates the study of the pathophysiology of MASLD and the evaluation of treatments. These are simpler and cheaper models that allow results to be obtained more quickly and which, although they are not identical to humans, have a carbohydrate/lipid metabolism and liver physiology similar to those of mammals,\" says the UB professor.\n\nThe results show that the combination of the two drugs reverses the fat accumulation in the liver induced by a diet high in fat and fructose. In addition, in the rat model, the combined administration of half a dose of pemafibrate and half a dose of telmisartan was found to be as effective as a full dose of either drug in reducing fat accumulation. \"Combination therapy with drugs acting on different pathogenic pathways may be a better strategy than monotherapy, thanks to possible synergistic effects and reduced toxicity related to the use of lower doses of each drug,\" Alegret points out.\n\nThe combination of these two drugs would be beneficial not only for liver disease, but also because \"it lowers blood pressure and cholesterol levels, and all this would result in a lower cardiovascular risk,\" she stresses.\n\n​​​​​​​Different lipid-lowering mechanisms The study also found that each drug works by different mechanisms and describes, for the first time, the key role of the PCK1 protein in telmisartan-derived hepatic lipid lowering. \"Telmisartan is a drug that has been used in other models of MASLD, but mostly in more advanced stages of the disease, and its beneficial effects have been attributed mainly to anti-inflammatory and anti-fibrotic effects. But in the early stages of the disease there is no inflammation or fibrosis yet, only lipid accumulation,\" explains the researcher.\n\nResearchers have now found that the amount of PCK1 protein in the livers of MASLD animals was reduced and that treatment with telmisartan restored its levels to normal. \"This increase in PCK1 diverts the flux of metabolites from lipid synthesis to glucose synthesis. This increase in glucose production could be negative if the glucose were exported and accumulated in the blood, as it could lead to diabetes, but we have noticed that this is not the case,\" says the UB professor.\n\nStill far from clinical application\n\nDespite these promising results, the researchers point out that, as this is a study using animal models, they are still far from patients. \"In order to be translated into a treatment for MASLD patients, clinical studies would be needed to show that the benefits observed in animal models also occur in humans,\" says Alegret. ​​​​​​​ In any case, the results raise new questions, such as whether the drugs will be equally effective in more advanced stages of the disease, when fibrosis is present. The research team is therefore already working on new studies in animal models of diet-induced liver fibrosis. \"In addition, we will develop a dual model involving liver fibrosis and cardiovascular disease to see if the beneficial action is observed not only in the liver, but also in the reduction of atherosclerosis,\" he concludes.",
      "url": "https://www.sciencedaily.com/releases/2025/10/251011105531.htm",
      "source": "Latest Science News -- ScienceDaily",
      "published": "2025-10-12",
      "sentiment_score": 0.85,
      "reasoning": "The article reports a significant scientific breakthrough in treating metabolic dysfunction-associated steatotic liver disease (MASLD), a widespread condition affecting one in three adults globally. The discovery that two existing drugs, when combined, can reduce liver fat and cardiovascular risks offers a promising, safer, and more effective therapeutic option with broad public health implications. The study is detailed, focused, and highlights a novel mechanism involving the PCK1 protein, providing substantial context and potential for future clinical application.",
      "category": "Health",
      "personality_title": "Two approved drugs together reduce liver fat and heart risks in fatty liver disease models",
      "personality_presentation": "**Context** – Metabolic dysfunction-associated steatotic liver disease (MASLD), often called fatty liver disease, affects about one in three adults worldwide. It happens when too much fat builds up inside liver cells, which can harm the liver and increase the chance of heart problems.\n\n**What happened** – Scientists at the University of Barcelona tested two existing drugs, pemafibrate (used to lower fats in the blood) and telmisartan (used for high blood pressure), on animal models of MASLD. They found that using both drugs together reduced liver fat more effectively than using either drug alone. This combination also lowered risks linked to heart disease. They used rats and zebrafish larvae to study how the drugs work and discovered a new role for a protein called PCK1 in controlling liver fat.\n\n**Impact** – This finding is important because current treatments for MASLD are limited and often unsafe in early stages. The tested drugs are already known to be safe for humans, which could make future treatment easier and faster to develop. The combination not only helps reduce liver fat but also lowers blood pressure and cholesterol, which together reduce heart risks. The discovery about the PCK1 protein helps scientists understand how telmisartan helps reduce liver fat in early disease stages.\n\n**What's next step** – Although these results are promising, they come from animal studies, so researchers need to run clinical trials to see if the drugs work the same way in people. The team is also planning more studies to test if the drugs help in later disease stages when liver scarring occurs and to explore benefits for heart disease connected to MASLD.\n\n**One-sentence takeaway** – Combining two safe, existing drugs shows promise in reducing liver fat and heart risks in fatty liver disease models, opening the door for new treatment options after further testing in humans.\n",
      "personality_title_fr": "Deux médicaments approuvés réduisent ensemble la graisse du foie et les risques cardiaques dans la maladie du foie gras",
      "personality_presentation_fr": "**Contexte** – La maladie hépatique stéatosique associée à un dysfonctionnement métabolique (MASLD), souvent appelée maladie du foie gras, touche environ un adulte sur trois dans le monde. Elle survient lorsque trop de graisse s'accumule dans les cellules du foie, ce qui peut endommager le foie et augmenter le risque de problèmes cardiaques.\n\n**Ce qui s’est passé** – Des chercheurs de l’Université de Barcelone ont testé deux médicaments existants, le pemafibrate (utilisé pour réduire les graisses dans le sang) et le télmisartan (utilisé pour l’hypertension), sur des modèles animaux de MASLD. Ils ont découvert que l’utilisation des deux médicaments ensemble réduisait la graisse du foie plus efficacement que chacun pris séparément. Cette combinaison réduisait aussi les risques liés aux maladies cardiaques. Ils ont utilisé des rats et des larves de poisson zèbre pour étudier le fonctionnement des médicaments et ont découvert un nouveau rôle pour une protéine appelée PCK1 dans la gestion des graisses du foie.\n\n**Impact** – Cette découverte est importante car les traitements actuels pour la MASLD sont limités et souvent peu sûrs aux premiers stades. Ces médicaments sont déjà connus pour être sûrs chez l’homme, ce qui pourrait faciliter et accélérer le développement d’un futur traitement. La combinaison aide non seulement à réduire la graisse du foie, mais aussi la tension artérielle et le cholestérol, ce qui diminue ensemble les risques cardiaques. La découverte sur la protéine PCK1 aide à mieux comprendre comment le télmisartan réduit la graisse du foie aux premiers stades de la maladie.\n\n**Prochaine étape** – Bien que ces résultats soient prometteurs, ils proviennent d’études sur les animaux, donc il faudra des essais cliniques pour vérifier si les médicaments fonctionnent de la même manière chez les humains. L’équipe prévoit aussi d’autres études pour tester l’efficacité des médicaments aux stades plus avancés de la maladie, quand le foie est cicatrisé, et pour explorer les bénéfices sur les maladies cardiaques liées à la MASLD.\n\n**Résumé en une phrase** – La combinaison de deux médicaments sûrs et existants montre un potentiel pour réduire la graisse du foie et les risques cardiaques dans les modèles de maladie du foie gras, ouvrant la voie à de nouveaux traitements après des tests chez l’homme.\n",
      "personality_title_es": "Dos medicamentos aprobados reducen juntos la grasa hepática y riesgos cardíacos en modelos de enfermedad del hígado graso",
      "personality_presentation_es": "**Contexto** – La enfermedad hepática esteatósica asociada a disfunción metabólica (MASLD), conocida como enfermedad del hígado graso, afecta a cerca de uno de cada tres adultos en el mundo. Ocurre cuando se acumula demasiada grasa dentro de las células del hígado, lo que puede dañarlo y aumentar el riesgo de problemas cardíacos.\n\n**Qué pasó** – Investigadores de la Universidad de Barcelona probaron dos medicamentos existentes, pemafibrato (para reducir las grasas en la sangre) y telmisartán (para la presión alta), en modelos animales de MASLD. Descubrieron que usar ambos medicamentos juntos reducía la grasa en el hígado más que usarlos por separado. Esta combinación también disminuyó riesgos relacionados con enfermedades del corazón. Usaron ratas y larvas de pez cebra para estudiar cómo funcionan los medicamentos y hallaron un nuevo papel para una proteína llamada PCK1 en el control de la grasa hepática.\n\n**Impacto** – Este hallazgo es importante porque los tratamientos actuales para MASLD son limitados y a menudo inseguros en etapas tempranas. Estos medicamentos ya son seguros para humanos, lo que podría facilitar y acelerar el desarrollo de nuevos tratamientos. La combinación no solo ayuda a reducir la grasa hepática, sino también la presión arterial y el colesterol, reduciendo juntos los riesgos cardíacos. El descubrimiento sobre la proteína PCK1 ayuda a entender cómo el telmisartán reduce la grasa en el hígado en etapas iniciales.\n\n**Próximo paso** – Aunque los resultados son prometedores, provienen de estudios en animales, por lo que se necesitan ensayos clínicos para confirmar si los medicamentos funcionan igual en personas. El equipo también planea más estudios para probar si los medicamentos ayudan en etapas avanzadas de la enfermedad cuando hay cicatrices en el hígado, y para explorar beneficios en enfermedades cardíacas vinculadas con MASLD.\n\n**Resumen en una frase** – La combinación de dos medicamentos seguros y existentes muestra potencial para reducir la grasa hepática y riesgos cardíacos en modelos de enfermedad del hígado graso, abriendo camino a nuevos tratamientos tras pruebas en humanos.\n",
      "image_url": "public/images/news_image_Two-common-drugs-could-reverse-fatty-liver-disease.png",
      "image_prompt": "A detailed, warm painting depicting a healthy liver shaped like a golden shield being gently cleansed by two glowing capsules—one blue and one green—flowing together like a calm river, surrounded by subtle symbolic representations of a zebrafish and a rat silhouette in the background, all rendered in soft, natural earth tones and gentle pastels."
    },
    {
      "title": "Naked mole rats live for decades — genetic tweaks reveal insights into ageing",
      "summary": "Nature, Published online: 09 October 2025; doi:10.1038/d41586-025-03279-yFour subtle changes to an enzyme might explain the hairless rodents’ longevity.",
      "content": "Naked mole rats (Heterocephalus glaber) can live for around 30 years. Credit: Getty\n\nFour subtle tweaks to an enzyme could help explain why naked mole rats’ can live for nearly 30 years, an unusually long lifespan for a creature its size.\n\nThe naked mole rat (Heterocephalus glaber), native to the Horn of Africa and parts of Kenya, has drawn attention from researchers because its genetic make-up is closer to humans than it is to mice, making the burrowing rodent an ideal model for studying ageing and longevity.\n\nIn a study1, published in Science today, researchers in China show that changes to the enzyme cGAS (cyclic guanosine monophosphate–adenosine monophosphate synthase) enhance the animal’s ability to repair genetic damage that leads to ageing. In humans and mice, the enzyme can suppress DNA repair.\n\nDrivers of ageing\n\nAn accumulation of genetic mutations and DNA damage during cell division is a significant driver of ageing and age-related diseases. A process called homologous recombination (HR) is a crucial DNA-repair pathway, and defects in this process are linked to premature ageing and cancer.\n\nDuring the HR process in humans and mice, cGAS enzyme gets pulled away from the damaged DNA by another protein, disrupting the repair.\n\nZhiyong Mao, co-author of the study and a molecular biologist at Tongji University in Shanghai, China, and his colleagues wanted to investigate whether a similar process occurs in naked mole rats. They found that four specific amino acid substitutions in the enzyme prevent it from breaking down too quickly after DNA damage. The persistence of cGAS means that the enzyme can connect more effectively with other DNA repair proteins that help to boost the cell’s ability to fix broken DNA.\n\nEnzyme removal\n\nWhen cGAS was removed from the animal’s cells using the gene-editing tool CRISPR–Cas9, DNA damage accumulated. The team also showed that fruit flies (Drosophila) that were engineered to express human cGAS containing the four mutations, which are specific to the naked mole rat, lived longer than flies expressing the human version of the enzyme.",
      "url": "https://www.nature.com/articles/d41586-025-03279-y",
      "source": "Nature",
      "published": "2025-10-13",
      "sentiment_score": 0.85,
      "reasoning": "The article reports a significant scientific breakthrough revealing genetic mechanisms behind the naked mole rat's exceptional longevity. This discovery has broad implications for understanding ageing and potentially developing therapies to improve human healthspan and combat age-related diseases. The study is detailed and focused on a single impactful topic with clear real-world benefits.",
      "category": "Health",
      "personality_title": "Four enzyme changes help naked mole rats live long lives",
      "personality_presentation": "**Context** – Naked mole rats are small rodents from Africa known for living about 30 years, much longer than other animals their size. Scientists study them because their genes are closer to humans than mice, making them useful for learning about ageing.\n\n**What happened** – Researchers in China found that four small changes in an enzyme called cGAS help naked mole rats repair damaged DNA better. DNA damage builds up over time and causes ageing. Usually, in humans and mice, this enzyme stops DNA repair, but in naked mole rats, the changes let the enzyme work longer and help fix DNA.\n\n**Impact** – This discovery explains part of why naked mole rats live so long. By keeping the enzyme active, their cells can fix damage that normally speeds up ageing. The study also showed that fruit flies with the naked mole rat version of the enzyme lived longer, proving the changes can help other animals too.\n\n**What's next step** – Scientists may use this knowledge to develop new treatments that improve DNA repair in humans. This could lead to ways to slow down ageing or prevent age-related diseases like cancer.\n\n**One-sentence takeaway** – Small changes in a key enzyme help naked mole rats fix DNA damage better, contributing to their long lives and offering clues for human ageing research.",
      "personality_title_fr": "Quatre modifications enzymatiques aident les rats-taupes nus à vivre longtemps",
      "personality_presentation_fr": "**Contexte** – Les rats-taupes nus sont de petits rongeurs d'Afrique connus pour vivre environ 30 ans, bien plus longtemps que d'autres animaux de leur taille. Les scientifiques les étudient car leurs gènes sont plus proches de ceux des humains que des souris, ce qui les rend utiles pour comprendre le vieillissement.\n\n**Ce qui s'est passé** – Des chercheurs en Chine ont découvert que quatre petites modifications d'une enzyme appelée cGAS aident les rats-taupes nus à mieux réparer l'ADN endommagé. Les dégâts sur l'ADN s'accumulent avec le temps et causent le vieillissement. Habituellement, chez l'humain et la souris, cette enzyme bloque la réparation, mais chez le rat-taupe nu, ces changements permettent à l'enzyme de rester active plus longtemps et d'aider à réparer l'ADN.\n\n**Impact** – Cette découverte explique en partie pourquoi les rats-taupes nus vivent si longtemps. En maintenant l'enzyme active, leurs cellules peuvent réparer des dégâts qui accélèrent normalement le vieillissement. L'étude a aussi montré que des mouches avec la version de l'enzyme du rat-taupe nu ont vécu plus longtemps, prouvant que ces changements peuvent aider d'autres animaux.\n\n**Prochaine étape** – Les scientifiques pourraient utiliser ces connaissances pour développer de nouveaux traitements améliorant la réparation de l'ADN chez l'humain. Cela pourrait permettre de ralentir le vieillissement ou prévenir des maladies liées à l'âge comme le cancer.\n\n**Résumé en une phrase** – De petites modifications d'une enzyme clé aident les rats-taupes nus à mieux réparer l'ADN, ce qui contribue à leur longue vie et offre des pistes pour la recherche sur le vieillissement humain.",
      "personality_title_es": "Cuatro cambios en una enzima ayudan a los ratas topo desnudos a vivir más tiempo",
      "personality_presentation_es": "**Contexto** – Los ratas topo desnudos son pequeños roedores de África que pueden vivir unos 30 años, mucho más que otros animales de su tamaño. Los científicos los estudian porque sus genes son más parecidos a los humanos que a los de los ratones, lo que los hace útiles para entender el envejecimiento.\n\n**Qué pasó** – Investigadores en China descubrieron que cuatro pequeños cambios en una enzima llamada cGAS ayudan a los ratas topo desnudos a reparar mejor el ADN dañado. El daño en el ADN se acumula con el tiempo y causa envejecimiento. En humanos y ratones, esta enzima suele bloquear la reparación, pero en los ratas topo desnudos, los cambios permiten que la enzima funcione más tiempo y ayude a reparar el ADN.\n\n**Impacto** – Este hallazgo explica por qué los ratas topo desnudos viven tanto tiempo. Al mantener la enzima activa, sus células pueden reparar daños que normalmente aceleran el envejecimiento. El estudio también mostró que las moscas con la versión de la enzima del rata topo desnudo vivieron más, demostrando que estos cambios pueden ayudar a otros animales.\n\n**Próximo paso** – Los científicos podrían usar esta información para crear tratamientos que mejoren la reparación del ADN en humanos. Esto podría ayudar a retrasar el envejecimiento o prevenir enfermedades relacionadas con la edad como el cáncer.\n\n**Conclusión en una frase** – Pequeños cambios en una enzima clave permiten a los ratas topo desnudos reparar mejor el ADN, lo que ayuda a su larga vida y da pistas para la investigación del envejecimiento humano.",
      "image_url": "public/images/news_image_Naked-mole-rats-live-for-decades-genetic-tweaks-re.png",
      "image_prompt": "A detailed, warm-toned painting of a naked mole rat gently cradled within a glowing, intricate network of DNA strands and molecular structures, symbolizing enhanced genetic repair, with subtle representations of enzyme shapes weaving harmoniously through the strands, set against a soft, natural background of earth tones."
    }
  ]
}